Hepion (HEPA) Back in the Spotlight, Gains 230% in May.
Hepion (HEPA) Phase 2 ‘ALTITUDE-NASH’ Trial Achieves Primary and Secondary Endpoints, Including Improvement in Liver Function and...
Ardelyx (ARDX) Resubmits New Drug Application to FDA.
WALTHAM, Mass., April 18, 2023 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company founded with a mission to discover, develop...
And we Have Another Triple! Ardelyx (ARDX) Touches $5.00, up 333%.
LIVE QUOTE
Longer Term Chart
Ardelyx Enters the Danger Zone* With Tenapanor.
And We Have a $26.4 Billion Winning Trifecta!
THREE PREVIOUS WINNERS*
Immunomedics (IMMU) $3 to $87 up 2,800%, a gain of $20.7 billion. Acquired...
We’re Bearish, but we’re up 243% in Provention Bio (PRVB) Today.
And up 416%, from Adding it to 2022 Watch List!
Great way to wake up after a night of...
Unicycive (UNCY) Shoots and Scores, up 40% Today!
We're up 126% Since December, and That Ain't Bad.
Note: This isn't the end, it's just the...
Booya. We’re up 143% With Ardelyx (ARDX) in Three Months – and That Ain’t...
Ardelyx Adds 16% to $3.82 as Wedbush Upgrades After Q4 Earnings.
Ardelyx ( NASDAQ: ARDX ) gained 35%...
SILO Pharma (SILO) Gains 53%
For Now, Volatility Remains and the Traders, Seem to be Having the Most Fun.
Silo Pharma Gains 53%...
He Shoots And He Scores. Ardelyx (ARDX) Gains 78%. Happy New Year!
Ah yes, and Gains Come to the Patient, as the FDA Moves the Ardelyx Ball Further Along.
Provention Bio (PRVB) Gains 26% Last Week.
We're up 106% From Adding to the 2022 Watch List Last July. And up 26% a Week After Urging Holders to Calm...
Latest article
Adding Quantum Pharmaceutical (QNTM) $4.10 to Reverse Split Stock Watch List.
119% Gain Post Split
Nine Page Summary Report on GeoVax (GOVX)
This is a great long-term story. We’re telling you.
(March 2024) When we finished writing our earlier...
GeoVax (GOVX) Provides First Half 2024 Business Update.
Award of BARDA Project NextGen contract represents a significant milestone event;
Total value...
